• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

    2/26/26 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email

    WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada's biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Emergent and Canada and reinforce Canada's commitment to long-term readiness and advanced strategic stockpiling. Emergent will receive more than $35M million CAD in orders in 2026.

    Under these agreements, Emergent will supply four medical countermeasures to protect against or treat biological threats. Committed annual procurements from Canadian authorities will help ensure continuous production and reliable supply of these critical countermeasures, as well as surge manufacturing capacity if required. Several of the medical countermeasures supplied under these agreements are manufactured at Emergent's Health Canada–licensed facility in Canada, reinforcing domestic production capacity for critical health security assets, supporting highly skilled biomanufacturing jobs, and strengthening Canada's capability to respond to biological threats.

    Emergent specializes in developing, manufacturing and supplying medical countermeasures for national security and health preparedness through its network of USMCA-compliant facilities. Emergent offers partners an innovative supply model through which it produces drug substance on a rolling basis with annual conversion to finished drug product. This approach strengthens customer preparedness, supports secure supply chains and ensures that inventory can be rapidly converted and deployed as threats evolve. These products support how governments respond to emergencies and help protect the public from potential threats.

    These procurements are an example of how defence and public health agencies can collectively ensure preparedness for the threats of today. This effort to stockpile critical medical countermeasures demonstrates Canada's leadership in international health preparedness.

    "Health security is an essential pillar of Canada's national security. Protecting Canadians from biological threats requires the same vigilance, preparedness, and strategic foresight that we apply across our defence posture. Canada's new Defence Industrial Strategy reinforces this commitment by identifying medical countermeasures as a key sovereign capability and by directing targeted investments to strengthen domestic biodefence capacity. By strengthening our national stockpiles and partnering with trusted Canadian suppliers, we continue to build a more resilient, self‑reliant health security ecosystem that protects our forces, our communities, and our sovereignty now and into the future," said Major General Scott Malcolm, Surgeon General, Canadian Armed Forces.

    "We are proud to continue our longstanding collaboration with the Public Health Agency of Canada and the Department of National Defence as they implement a forward looking, strategic preparedness framework, serving as a model of best practices in health preparedness," said Dr. Chris Sinclair, vice president and head of global preparedness at Emergent. "Through innovative supply models, long-term public-private collaboration, and coordination across government agencies, Canada is able to strengthen its approach to public health preparedness and national security."

    About Emergent BioSolutions

    At Emergent, our mission is to protect and save lives. For over 25 years, we've been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today's health challenges and tomorrow's threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

    Investor Contact:

    Richard S. Lindahl

    Executive Vice President, CFO

    [email protected]

    Media Contact:

    Assal Hellmer

    Vice President, Communications

    [email protected]



    Primary Logo

    Get the next $EBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel, Corp Sec Perl Jessica covered exercise/tax liability with 918 shares, decreasing direct ownership by 1% to 67,469 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:11:20 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Quality & Ethics, and CPL Glessner Coleen returned $315,009 worth of shares to the company (28,847 units at $10.92) and covered exercise/tax liability with 2,852 shares, decreasing direct ownership by 22% to 112,620 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:09:25 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Products Business Williams Paul Anthony returned $94,513 worth of shares to the company (8,655 units at $10.92) and covered exercise/tax liability with 1,022 shares, decreasing direct ownership by 11% to 76,194 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    2/10/26 7:07:24 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of

    2/26/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

    GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company's common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company's common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. "In 2025, we were able to return value to shareholders through share repurchases as we continued to make progress on our multi-year transformation," said Joe Papa, president and CEO of Emergent. "This new approval ref

    2/26/26 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

    WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada's biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Emergent and Canada and reinforce Canada's commitment to long-term readiness and advanced strategic stockpiling. Emergent will receive more than $35M million CAD in orders in 2026. Under these agreeme

    2/26/26 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/15/25 4:02:40 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    SEC Filings

    View All

    Emergent BioSolutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

    2/26/26 4:08:12 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Emergent BioSolutions Inc.

    SCHEDULE 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    2/9/26 6:33:12 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Emergent BioSolutions Inc.

    SCHEDULE 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    1/30/26 1:31:10 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

    H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

    12/30/24 7:24:57 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

    Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

    8/22/24 7:22:39 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

    3/7/24 10:14:18 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Leadership Updates

    Live Leadership Updates

    View All

    Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

    GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) announced today that Dr. Louis W. Sullivan will retire from the company's Board of Directors effective November 14 after 19 years of service to the company and its shareholders. "For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent's mission to protect and save lives," said Joe Papa, president and CEO of Emergent. "On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best." Dr. Sullivan served on Emergent's Board of Directors since 2006, and most recently served as chair of the

    11/12/25 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

    Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an

    11/4/24 7:30:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

    Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg

    10/8/24 5:32:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of

    2/26/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Reports Third Quarter 2025 Financial Results

    Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior yearThird Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38%Raising the Full Year 2025 Revenue and Profitability GuidanceStrong Sequential Naloxone Revenue Growth, Primarily Driven by NARCAN® Nasal Spray, QoQ Through Q3 2025 GAITHERSBURG, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results

    10/29/25 4:15:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/8/24 5:23:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    9/10/24 12:09:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care